2UV Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Applied Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.90 |
| 52 Week High | US$9.45 |
| 52 Week Low | US$1.65 |
| Beta | 2.02 |
| 11 Month Change | 12.30% |
| 3 Month Change | 70.17% |
| 1 Year Change | 434.86% |
| 33 Year Change | -25.83% |
| 5 Year Change | -42.95% |
| Change since IPO | 5.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2UV | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 12.7% | -0.2% | 0.8% |
| 1Y | 434.9% | -16.9% | 9.1% |
Return vs Industry: 2UV exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 2UV exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 2UV volatility | |
|---|---|
| 2UV Average Weekly Movement | 22.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2UV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2UV's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 37 | Shoshana Shendelman | www.appliedtherapeutics.com |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company’s lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.
Applied Therapeutics, Inc. Fundamentals Summary
| 2UV fundamental statistics | |
|---|---|
| Market cap | €1.07b |
| Earnings (TTM) | -€178.47m |
| Revenue (TTM) | n/a |
-5,263x
P/S Ratio-6.0x
P/E RatioIs 2UV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2UV income statement (TTM) | |
|---|---|
| Revenue | -US$212.00k |
| Cost of Revenue | US$52.35m |
| Gross Profit | -US$52.56m |
| Other Expenses | US$134.75m |
| Earnings | -US$187.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 24,794.34% |
| Net Profit Margin | 88,353.77% |
| Debt/Equity Ratio | 0% |
How did 2UV perform over the long term?
See historical performance and comparison